Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer

被引：2
作者：
Wander, S. A.
Spring, L. M.
Stein, C. R.
Yuen, M.
Zangardi, M.
O'Shaughnessy, J.
Bardia, A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-18-39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-18-39
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.
    Tolaney, Sara M.
    Lin, Nancy U.
    Thornton, Donald
    Klise, Suzanne
    Costigan, Timothy Michael
    Turner, P. Kellie
    Anders, Carey K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Clinical characteristics, demographics, and outcomes in hormone-receptor (HR plus ) positive metastatic breast cancer (MBC) patients treated with palbociclib.
    Landry, Chrystal Ann
    Dimitrova, Maya
    Ru, Meng
    Teplinsky, Eleonora
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [24] Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2-advanced breast cancer: Analysis of the MONARCH trials
    Rugo, H. S.
    Tolaney, S. M.
    Huober, J.
    Toi, M.
    Andre, V.
    Barriga, S.
    Forrester, T.
    Sledge, G. W.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
    Li, Allen
    Naik, Arpana
    Johnson, Nathalie
    Goodyear, Shaun
    Johnson, Brett
    Park, Byung
    Corless, Christopher
    Gray, Joe
    Mills, Gordon
    Mitri, Zahi
    CANCER RESEARCH, 2021, 81 (04)
  • [26] SG Improves OS in HR+/HER2-Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
  • [27] Treatment of metastatic HR+, HER2-Breast Cancer with Abemaciclib Significant Prolongation of progression-free and Overall Survival - also in Subgroups
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (09) : 485 - 485
  • [28] Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer
    Murtuza Rampurwala
    Kari B. Wisinski
    Mark E. Burkard
    Sima Ehsani
    Ruth M. O’Regan
    Lakeesha Carmichael
    KyungMann Kim
    Jill Kolesar
    Amye J. Tevaarwerk
    Investigational New Drugs, 2017, 35 : 87 - 94
  • [29] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024, : 2647 - 2659
  • [30] Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Usami, Eiseki
    Noguchi, Yoshihiro
    Yoshimura, Tomoaki
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (06) : 1258 - 1266
12345